期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不同化疗方案治疗弥漫大B细胞淋巴瘤的疗效观察 被引量：1

下载PDF
导出
摘要 目的比较利妥昔单抗联合CHOP方案与常规CHOP方案治疗弥漫大B细胞淋巴瘤(DLBCL)的效果、不良反应发生等。方法回顾性分析我科2007年1月至2009年1月治疗的41例DLBCL患者,按照治疗方式的不同,将采用利妥昔单抗联合CHOP(R-CHOP)方案的18例患者列入观察组,而常规CHOP方案治疗的23例患者为对照组,比较两组患者的疗效及不良反应的发生情况。结果①观察组患者CR+PR明显高于对照组(P<0.05),且BCL-2阳性表达或者IPI评分超过2分的患者采用R-CHOP治疗方案能获得更高的CR率(P<0.05)。②观察组总生存期为32.9个月,明显高于对照组(P<0.05)。③两组患者不良反应的发生率差异无统计学意义(P>0.05)。结论利妥昔单抗联合CHOP化疗能够提高弥漫大B细胞性淋巴瘤患者的疗效,且不良反应未见增加,安全性较高。
作者 宋通微
机构地区 深圳市人民医院血液内科
出处 《海南医学》 CAS 2012年第23期30-32,共3页 Hainan Medical Journal
关键词 利妥昔单抗 弥漫大B细胞淋巴瘤 CHOP方案
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence pat- terns by WHO subtype in United Sates, 1992-2001 [J]. Blood, 2006, 107(1): 265-276.
  • 2张之南.血液病学[M].北京:人民卫生出版社,2003.1101-1106.
  • 3Zelenetz AD, Hoppe RT. NCCN non-hodgkin's lymphoma practice guidelines panel [J]. Cancer Control, 2001, 8(2): 102-113.
  • 4徐卫,李建勇,张智弘,仇红霞,钱思轩,吴汉新,陆化,盛瑞兰.R-CHOP方案与CHOP方案治疗初治弥漫性大B细胞淋巴瘤的临床研究[J].中国实验血液学杂志,2008,16(4):933-937. 被引量：21
  • 5Sehn LH, Jane DJ, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia [J]. J Clin On- col, 2005, 23(22): 5027-5033.
  • 6Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma [J]. J Clin Oncol, 2006, 24(19): 3121-3127.
  • 7林桐榆,张红雨,黄岩,管忠震,沈悌,石远凯,朱军,克晓燕,王华庆,沈志祥,于世英,刘霆,施笑利.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426. 被引量：48
  • 8Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemo- therapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group [J]. Lancet Oncol, 2006, 7(12): 379-391.
  • 9Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP ( R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma(DLBCL) [J]. Blood, 2003, 101(12): 4279.
  • 10Vose JM, Link BK, Grossbard ML, et al. Long term follow-up of a phase II study of rituximab in combinationwith CHOP chemothera- py in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL) [J]. Blood, 2005, 46(11): 1569-1573.

二级参考文献20

  • 1Coiffier B, Lepage E. Prognosis of aggressive lymphomas :a study of five prognostic models with patients included in the LNH-84 regimen [J]. Blood, 1989,74(2) :558-564.
  • 2Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 [J]. Blood, 1994,83(2) :435-445.
  • 3Coiffier B, Haioun C, Ketterer N, et al. Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma., a multicenterphase Ⅱ study [J]. Blood, 1998,92(6) : 1927-1932.
  • 4The Non-Hodgkin's Lymphoma Pathologic Classification Project.National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage [J]. Cancer, 1982,49(10) : 2112-2135.
  • 5Tedder TF, Engel P. CD20:a regulator of cell-cycle progression of B lymphocytes [J]. Immunol Today, 1994,15(9):450-454.
  • 6Demidem A,(IDEC-C2B8)lymphoma cellCancer BiotherLam T, Alas S, et al. Chimeric anti-CD20 monoclonal antibody sensitizes a B cell line to cell killing by cytotoxic drugs [J].Radiopharm, 1997, 12(3) : 177-186.
  • 7Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [J]. N Engl J Med, 2002,346(4) :235-242.
  • 8McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond totreatment program [J]. J Clin Oncol, 1998,162833.a four-dose(8):2825-2833.
  • 9Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD [J]. Ann Intern Med,1986, 104(6) : 757-765.
  • 10Elias L,Portlock CS,Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide,adriamycin, vincristine and prednisone (CHOP) [J]. Cancer,1978.42(4) : 1705-1710.

共引文献323

同被引文献14

  • 1凌青霞,金宏慧,郑建铭,施光峰.甘草酸二铵脂质复合物肠溶胶囊与甘草酸二铵胶囊对照治疗慢性病毒性肝炎687例荟萃分析[J].中华肝脏病杂志,2014,22(6). 被引量：14
  • 2Takai S, Tsururni H, Ando K, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury fol- lowing chemotherapy [J]. Eur J Haematol, 2005, 74(2): 158-165.
  • 3Miyazaki M, Rosenblum JS, Kasahara Y, et al. Determination of en- zymatic source of alanine aminotransferase activity in serum from dogs with liver injury [J]. J Pharmacol Toxicl Methods, 2009, 60(3): 307-315.
  • 4Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis [J]. Hepatology, 1997, 26(3): 664-665.
  • 5Shi Q, Hong H, Senior J, et al. Biomarkers for drug-in-dueced liver injury [J]. Expert Rev Gastroenterol Hepatol, 2010, 4(2): 225-234.
  • 6Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of chernotherapy [J]. Semin Oncol, 2006, 33(1): 50-67.
  • 7Daly AK. Drug-induced liver injury: past, present and future [J]. Pharmacogenomics, 2010, 11(5): 607-608.
  • 8Tsuruoka N, Abe K, Wake K, et al. Hepatic protection by glycyrrhi- zin and inhibition of iNOS expression in concanavalin A-induced liver injury in mice [J]. Inflamm Res, 2009, 58(9): 593-594.
  • 9Kim R, Em Mi, Tanabe K, et al. Therapeutic potential of antisense Bcl-2 as achemosensitizer for cancer therapy [J]. Cancer, 2004, 101 (11): 2491-2502.
  • 10唐明珍,张松.甘利欣在治疗肿瘤化疗所致肝损害中的临床应用探讨[J].齐齐哈尔医学院学报,2012,33(9):1169-1170. 被引量：6

引证文献1

二级引证文献2

海南医学
2012年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部